Pentixapharm Advances PentixaTher in AML Trial

Pentixapharm Holding AG has announced the advancement of its radiotherapeutic candidate, PentixaTher, to the fourth dose level in the PENTILULA Phase 1/2 trial for acute myeloid leukemia (AML). This progression follows a favorable safety profile at the third dose level, approved by the independent Data Safety Monitoring Board. As the trial moves to 10 GBq, it enters a potentially more effective dose range. If safety signals remain positive, further escalation to a fifth dose level of 12.5 GBq is anticipated.

AML, with approximately 20,000 new cases annually in the US and 17,000 in Europe, presents limited treatment options and poor prognosis. Researchers and clinicians are hopeful that CXCR4-targeted radiopharmaceuticals like PentixaTher could significantly broaden therapeutic strategies. This stage of the trial aims to further validate the safety and clinical efficacy of PentixaTher, potentially impacting the treatment landscape for AML patients.